Centogene NV (CNTG) has released an update.
CENTOGENE N.V., a key player in providing data-driven solutions for rare and neurodegenerative diseases, has successfully concluded its 2024 Annual General Meeting with all proposed resolutions passed by shareholders. Key approvals included the adoption of a new supervisory board compensation structure, reappointment of Ernst & Young Accountants LLP as external auditor, and extended powers for the management board concerning share issuance and acquisition. The company continues to leverage its extensive biodatabank and multiomic technologies to support precision medicine and collaborate with over 50 pharma partners.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
